

Stabilis



Durvalumab



Tradename

Imfinzi	Argentina, Australia, Belgium, Brazil, Canada, Chile, Denmark, Finland, France, Germany, Great Britain, Hungary, Ireland, Italy, Japan, Luxembourg, Mexico, Norway, Peru, Romania, Spain, Sweden, Switzerland, United States of America
---------	---



Stability in solutions

		50 mg/ml	2-8°C		28			4767
		50 mg/ml	20-25°C		28			4767
		50 mg/ml	20-25°C		14			4772
		50 mg/ml	4°C		14			4772
		1 >> 15 mg/ml	2-8°C		30			4608
		1 >> 15 mg/ml	25°C		24			4608



























References

	Type	Publication
4608	Manufacturer	Durvalumab (Imfinzi - Summary of Product Characteristics, updated August 2021) Astra Zeneca 2021
4767	Journal	Almasi K, Thiesen J, Krämer I. Physicochemical stability of durvalumab (Imfinzi®) concentrate for solution in original vials after first opening. Pharmaceutical Technology in Hospital Pharmacy 2023 ;8,1
4772	Journal	Porlier A, Gagnon P-Y, Chénard V, Michael N-J, Simard C, Drolet B. Stability of Opened Durvalumab (IMFINZI) Vials. The Beginning of the End of Costly Product Wastage? J Pharm Sci 2023 ; 112, 9: 2412-2418.



Dictionary

 Anticancer drug	 injection
 Tradename	 Stability in solutions
 Container	 Molecule
 Concentration	 Temperature
 Storage	 Duration of stability
 Biosimilar	 conflicting data
 References	 partially used vials
 None	 Protect from light
 Day	 Light
 Not specified	 NaCl 0,9% or Glucose 5%
 Not specified	 Hour
 References	 Dictionary